LON:HIK - Hikma Pharmaceuticals Share Price, Forecast & News

Hikma Pharmaceuticals' stock was trading at GBX 1,828.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HIK shares have increased by 11.3% and is now trading at GBX 2,035. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Hikma Pharmaceuticals.

Hikma Pharmaceuticals declared a dividend on Thursday, February 27th. Shareholders of record on Thursday, March 19th will be given a dividend of GBX 0.30 per share on Thursday, May 7th. This represents a dividend yield of 1.22%. The ex-dividend date is Thursday, March 19th. This is a boost from Hikma Pharmaceuticals's previous dividend of $0.14. The official announcement can be accessed at this link. View Hikma Pharmaceuticals' dividend history.

7 analysts have issued 12 month price objectives for Hikma Pharmaceuticals' stock. Their forecasts range from GBX 1,850 to GBX 2,390. On average, they expect Hikma Pharmaceuticals' stock price to reach GBX 2,078 in the next year. This suggests a possible upside of 2.1% from the stock's current price. View analysts' price targets for Hikma Pharmaceuticals.

News coverage about HIK stock has trended positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Hikma Pharmaceuticals earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutHikma Pharmaceuticals.

Some companies that are related to Hikma Pharmaceuticals include Merck KGaA (MRK), Canopy Growth (WEED), Bausch Health Companies (BHC), Evotec (EVT), Aurora Cannabis (ACB), Aphria (APHA), Knight Therapeutics (GUD), HLS Therapeutics (HLS), Ecofibre (EOF), OrganiGram (OGI), Hexo (HEXO), Next Science (NXS), ICC Labs (ICC), HEXO (HEXO) and Benchmark (BMK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of HIK stock can currently be purchased for approximately GBX 2,035.

Hikma Pharmaceuticals has a market capitalization of £4.93 billion and generates £2.21 billion in revenue each year. Hikma Pharmaceuticals employs 8,400 workers across the globe. View additional information about Hikma Pharmaceuticals.

The official website for Hikma Pharmaceuticals is http://www.hikma.com/.

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.